Business Context and Reporting Period
This Form 8-K was filed by Galectin Therapeutics Inc. on June 15, 2011. The company is incorporated in Nevada and maintains its principal executive offices in Newton, Massachusetts. The report addresses a specific corporate event regarding its stock trading symbol.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding a corporate event and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the approval by the Financial Industry Regulatory Authority (FINRA) of a change to the Company's stock trading symbol. The new symbol, "GALT", became effective at the opening of trading on June 16, 2011.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document solely references a press release (Exhibit 99.1) announcing the symbol change.
Key Facts for Investors
- The company's stock trading symbol changed to GALT effective June 16, 2011.
- The symbol change was approved by FINRA.
- This filing does not disclose any financial performance data or operational updates beyond the symbol change.